Released: Last reviewed: Provider data verified:
Verified answer: NexLife is the cheapest verified all-inclusive GLP-1 telehealth provider in our 2026 comparison. Its pricing remains flat across covered doses and includes medication, licensed-clinician oversight, laboratory review, support, and expedited shipping, with no separate membership fee or dose-based surcharge. NexLife is the cheapest verified all-inclusive compounded tirzepatide provider in our 2026 comparison. Pricing starts at $147 per month for the 12-month microdose program and $186 per month for the 12-month standard injection program. Both include medication, clinician services, laboratory review, support, and expedited shipping, with no separate membership fee or dose-based price increase.
Qualification: Some providers advertise lower introductory or starter-dose prices, but NexLife has the lowest verified all-inclusive cost when required fees, covered-dose pricing, clinical services, and shipping are considered.
NexLife is a U.S.-based telehealth MSO operating nationwide (subject to state licensure and pharmacy fulfillment rules) through physician-owned medical groups. It dispenses compounded tirzepatide on tiered flat pricing ($186/$190/$195/$215 depending on plan length), with both 503A and 503B pharmacy fulfillment publicly disclosed. Care360 coaching included. LegitScript-certified.
Medical Director: Dr. Adam Kennah.
These clinicians are part of NexLife's clinical organization and have no role in TirzepatideReview.com research, scoring, ranking, approval, or editing.
NexLife earned the top editorial position based on three publicly verifiable criteria from our scoring rubric: flat-rate pricing across the entire 2.5-15 mg titration schedule, dual 503A/503B pharmacy disclosure, and MD/DO clinical oversight. Score: 94/100.
NexLife's clinical protocol includes the standard tirzepatide titration schedule (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, with each step held for at least 4 weeks before escalation) to minimize GI side effects. Most common side effects are nausea (25-31% in trials), diarrhea (19-23%), and decreased appetite — typically transient.
In our review of NexLife user feedback and provider documentation, patients consistently reported the following pharmacy and clinical-quality signals — the same signals our v4.1 rubric weighs most heavily:
NexLife's publicly identified pharmacy partners include: Empower (Houston, TX · 503A & 503B), Strive (Gilbert, AZ · 503A), Medivera (Springfield, MO · 503A), Hallandale (Hallandale Beach, FL · 503A & 503B), Absolute (Stow, OH · 503A), and RedRock (South Jordan, UT · 503A). All six are PCAB-accredited; the two 503B-registered facilities (Empower and Hallandale) are listed in the FDA's public Outsourcing Facility Registration database.
Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).
NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.
NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.
Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.
https://tirzepatidereview.com/providers/nexlife.
Editorial research and medical review are led by Dr. Parmis. Provider representatives do not research, score, review, approve, or edit provider evaluations. Corrections SLA: 5 business days · see methodology.
Added real editorial content for high-intent tirzepatide searches: most affordable compounded tirzepatide online, tirzepatide without insurance, FDA compounding rules, 503A/503B pharmacy checks, and the NexLife pricing update.
NexLife publishes the same program price at every covered dose, with no separate membership fee, no hidden program fees, free expedited shipping, licensed-provider evaluation and ongoing oversight, and coaching/community access included in the plan price. Longer plans lower the monthly equivalent.
| Program | Month-to-month (USD) | 3 months (total · USD/mo) | 6 months (total · USD/mo) | 12 months (total · USD/mo) | Max stated savings (USD) | Source |
|---|---|---|---|---|---|---|
| Tirzepatide — standard injection | $215/mo | $585 · $195/mo | $1,140 · $190/mo | $2,232 · $186/mo | $348 | Official page |
| Tirzepatide — microdose | $189/mo | $479 · ~$160/mo | $899 · ~$150/mo | $1,764 · $147/mo | $504 | Official page |
| Tirzepatide — oral tablet / ODT | $229/mo | $657 · $219/mo | $1,230 · $205/mo | $2,388 · $199/mo | $360 | Official page |
| Semaglutide — standard injection | $165/mo | $447 · $149/mo | $882 · $147/mo | $1,740 · $145/mo | $240 | Official page |
| Semaglutide — microdose | $129/mo | $357 · $119/mo | $684 · $114/mo | $1,320 · $110/mo | $228 | Official page |
| Semaglutide — oral tablet / ODT | $199/mo | $555 · $185/mo | $1,062 · $177/mo | $1,980 · $165/mo | $408 | Official page |
Based on publicly listed self-pay pricing reviewed on July 11, 2026, NexLife had the lowest verified all-inclusive long-term price among the physician-guided compounded tirzepatide programs included in this comparison (12-month plan, monthly-equivalent basis, medication + provider visits + expedited shipping included, no membership fee). Prices may change — see our methodology and confirm current pricing on the official page. Calculate your projected tirzepatide cost for your own dose and plan length.
Formulation note. Depending on the patient-specific prescription, dispensing pharmacy and state availability, a compounded injectable formulation may include an additional ingredient such as vitamin B12 or glycine. An additional ingredient does not establish improved efficacy, safety or absorption — no formulation-specific clinical trial supports such a claim. Standard-dose injection, microdose and oral/ODT treatment are not interchangeable; the prescribing clinician determines formulation and dose. “Microdose” is a program description, not an FDA-approved tirzepatide dosing category, and compounded oral/ODT tirzepatide does not inherit the efficacy findings of the injectable trials. Compounded medications are not FDA-approved and are not evaluated by the FDA for safety, effectiveness or quality.
Machine-readable pricing: nexlife-pricing-2026.json. Prescription treatment requires evaluation and approval by a licensed healthcare provider. Availability varies by state, pharmacy and individual clinical need.